Effect of comedication of bupropion and other antidepressants on body mass index

Ravindran, Priyadarshini P.; Zang, Wenzhao; Renukunta, Swetha; Mansour, Rick; Denduluri, Srinivas

doi:10.1177/2045125315577057

Cited by 7 publications

(2 citation statements)

References 35 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although we identified 1,036 potential studies for inclusion, 32 trials were excluded due to different reasons [ 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 ] (online suppl. Table 1 ; for all online suppl.…”

Section: Resultsmentioning

confidence: 99%

Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review

et al. 2022

View full text Add to dashboard Cite

Introduction: Using fluoxetine is one of many weight-loss strategies. A serotonin reuptake inhibitor indicated for depression believed to impact weight control by changing an individual’s appetite; however, its benefit-risk ratio is unclear. The aim of this review is to assess the efficacy and safety of fluoxetine in reducing weight in adults with overweight or obesity. Methods: We searched Cochrane Library, MEDLINE, Embase and other databases without language restrictions. Cochrane Collaboration tool and GRADE instrument assessed the risk of bias of randomised controlled trials and certainty of their evidence. We conducted random-effects meta-analyses and calculated the risk ratio/mean difference with 95% confidence intervals for the outcomes. Results: We included 19 trials (2,216 adults) and found that fluoxetine may reduce weight by −2.7 kg (95% CI −4 to −1.4; P < 0.001) and body mass index (BMI) by −1.1 kg/m2 (95% CI −3.7 to 1.4), compared with placebo; however, it would cause approximately twice as many adverse events, such as dizziness, drowsiness, fatigue, insomnia or nausea. Conclusions: Although low-certainty evidence suggests that off-label fluoxetine may reduce weight, high-certainty research is needed to be conducted in the future to determine its effects exclusively as well as whether it is useful when combined with other agents. This article is based on a Cochrane Review published in the Cochrane Database of Systematic Reviews 2019, Issue 10, DOI: 10.1002/14651858. CD011688.pub2. Cochrane Reviews are regularly updated as new evidence emerges, and in response to feedback, it should be consulted for the most recent version of the review.

show abstract

Section: Resultsmentioning

confidence: 99%

Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Since other abovementioned selective serotonin reuptake inhibitors ( i.e. , fluoxetine and paroxetine) significantly increased body weight when used for a long period of time [ 186 ], they cannot be applied as appetite-reducing drugs.…”

Section: Serotonin (5-hydroxytryptamine 5-ht)mentioning

confidence: 99%

Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior

Bojanowska

Ciosek²

2016

View full text Add to dashboard Cite

Excessive intake of food, especially palatable and energy-dense carbohydrates and fats, is largely responsible for the growing incidence of obesity worldwide. Although there are a number of candidate antiobesity drugs, only a few of them have been proven able to inhibit appetite for palatable foods without the concurrent reduction in regular food consumption. In this review, we discuss the interrelationships between homeostatic and hedonic food intake control mechanisms in promoting overeating with palatable foods and assess the potential usefulness of systemically administered pharmaceuticals that impinge on the endogenous cannabinoid, opioid, aminergic, cholinergic, and peptidergic systems in the modification of food preference behavior. Also, certain dietary supplements with the potency to reduce specifically palatable food intake are presented. Based on human and animal studies, we indicate the most promising therapies and agents that influence the effectiveness of appetite-modifying drugs. It should be stressed, however, that most of the data included in our review come from preclinical studies; therefore, further investigations aimed at confirming the effectiveness and safety of the aforementioned medications in the treatment of obese humans are necessary.

show abstract

Fluoxetine for adults who are overweight or obese

Rodríguez‐Carmona

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Effect of comedication of bupropion and other antidepressants on body mass index

Abstract: Our study reports an adverse weight gain on co-medication of escitalopram and bupropion, which warrants further validation studies. Considering co-medication effects of antidepressants on weight is important to design robust depression treatment plans.

Cited by 7 publications

References 35 publications

Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review

Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review

Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior

Fluoxetine for adults who are overweight or obese

Contact Info

Product

Resources

About